Introduction
Antibodies recognize and bind to antigen through their Fab segment. However, much of the biological activity of antibody is mediated through its Fc portion and, in particular, through interactions between Fc and Fc receptors found on a number of cells important for host defense. Some of these biological activities, such as virus neutralization, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell-mediated virus inhibition (ADCVI), and phagocytosis, are likely to play a role in preventing or modulating HIV infection.
Receptors for the Fc segment of immunoglobulin G (IgG) (Fcg receptors; FcgRs) are expressed on the surface of a number of cells that are involved, or potentially involved, in HIV infection, including natural killer (NK) cells, monocytes, macrophages, dendritic cells, and neutrophils [1] . With the exception of gd T cells, FcgRs are normally not found on T lymphocytes. In addition to the neonatal Fc receptor (not discussed in this review), five major FcgRs have been identified in humans: FcgRI, FcgRIIa, FcgRIIb, FcgRIIIa, and FcgRIIIb [1] . FcgRI and FcgRIIIa generally serve to activate cells and require an interaction with a separate immune tyrosine-activating motif (ITAM)-containing protein, such as the Fc receptor common g-chain or the CD3 z-chain. FcgRIIa is also an activating receptor but contains an ITAM in its cytoplasmic tail [2] . FcgRIIIb is linked to the plasma membrane by a glycosyl phosphatidylinositol anchor and is only found on neutrophils and eosinophils [1, 2] . FcgRIIb is exceptional in that it contains an immune tyrosine inhibitory receptor [immune tyrosine-based inhibitory motif (ITIM)] in its cytoplasmic tail and results in inhibition of activation [3] .
Both FcgRIIa and FcgRIIIa are encoded by polymorphic genes that result in phenotypically different receptors. In the case of FcgRIIa, a single-nucleotide polymorphism results in either a histidine (H) or an arginine (R) at amino acid position 131 [4, 5] . Both the H and R isoforms of the receptor bind all four IgG subclasses, but IgG2 binding to the R isoform is weak [6 ] . The HH and RR genotypes are each found in about 25% of individuals with European or African ancestry [7] [8] [9] [10] . This distribution is markedly skewed among Asians, in whom homozygosity for the H allele is found in about 50-60% and the homozygous R genotype is found in less than 10% [11, 12] . A polymorphism in the FcgRIIIa gene encodes either a phenylalanine (F) or a valine (V) at amino acid 158 [13] . The V isoform binds with all subclasses, but IgG2 binding is weak; the F isoform binds IgG1 with lower affinity than does the V isoform, and the F isoform does not bind either IgG2 or IgG4 [6 ] . Worldwide, the VV genotype has been found in about 10-20% of the population, and the FV and FF genotypes account for about 40-50% each [7, 8, 10, 11] . Importantly, the polymorphisms in both FcgRIIa and FcgRIIIa have been noted to influence susceptibility to or severity of a number of infectious and autoimmune diseases [14] . In this review, we will outline the current state of knowledge about the role of Fc-FcgR interactions in HIV infection, with particular attention paid to neutralization, ADCC, and ADCVI.
Fcg receptor-mediated inhibition and neutralization of HIV Neutralization has often been defined by the ability of the antibody Fab fragment to bind to epitopes on functional spikes of cell-free virions and to inhibit entry into susceptible cells. However, an FcgR-dependent mechanism of HIV inhibition involving the concomitant binding of Fab to the virus and Fc to FcgRs was detected in antigen-presenting cells (APCs) [15] [16] [17] . Involvement of Fc-FcgR interactions in this manner resulted in a marked augmentation of antibody-neutralizing activity on macrophages (about 1000-fold) and dendritic cells (about 100-fold) compared with lymphocytes lacking FcgRs. For macrophages, FcgRI was mainly involved [15] , whereas FcgRII was mostly implicated with monocyte-derived dendritic cells [17] and Langerhans or interstitial dendritic cells (Peressin M, personal communication). The specific pathway of virus degradation is under evaluation, but it is hypothesized that the binding of HIV-IgG immune complexes to FcgRs at the surface of APCs leads to viral endocytosis and degradation in acidic lysosomes.
The FcgR-mediated inhibitory activity was detected for the five well known neutralizing mAbs (2F5, 4E10, 2G12, b12, and 447-D) and, remarkably, for some nonneutralizing antibodies [referred to as nonneutralizing inhibitory antibodies (NNIAbs)]. It is noteworthy that only a small proportion of antibodies able to bind HIV-1 native particles, including some antibodies directed against the principal immunodominant domain of gp41, exhibit FcgR-mediated inhibitory activity. This finding strongly suggests that, as for classical neutralizing antibodies, special features are associated with the FcgR-mediated functional activity. The parameters associated with the NNIAbs remain to be defined, but preliminary experiments indicate that this inhibitory activity was not simply related to binding affinity of the antibodies to virus particles. NNIAbs were detected in sera from numerous, but not all HIV-infected individuals, indicating that such antibodies are frequently induced after infection and may thus also be induced by vaccination [16, 18 ] . As these antibodies were present in sera of numerous infected individuals, NNIAb may be of limited benefit once the infection has occurred. Indeed, these antibodies do not inhibit infection of CD4 þ lymphocytes, the principal HIV targets. However, as NNIAbs are powerful inhibitors of APC infection, their presence directly on or near mucosal surfaces could prevent infection of macrophages or dendritic cells, which are thought to be very early targets during sexual transmission of HIV.
Finally, in the case of antibodies directed against the membrane proximal external region (MPER) of gp41, neutralization may be augmented through a mechanism whereby FcgR (especially FcgRI) engagement provides a more favorable interaction between antibody and a prehairpin intermediate conformation of gp41 [19] . This suggestion has been made on the basis of enhanced neutralization by anti-MPER antibodies on TZMbl cells that were transfected to express FcgRs [19] ; the biological relevance of such a mechanism is not known.
Antibody-dependent cellular cytotoxicity
Antibody-dependent cellular cytotoxicity occurs when antibody forms a bridge between a target cell expressing foreign antigens and an effector cell bearing Fc receptors. With respect to HIV, target cells have usually consisted of cell lines coated with gp120, engineered to express HIV antigens or infected with HIV-1, and peripheral blood mononuclear cells (PBMCs), NKs, monocytes, or neutrophils have been used as effector cells. In any case, the result of the three-way interaction between target cell, antibody, and effector cell is target cell death, usually measured by the release of 51 Cr, dye, or enzymes [20] [21] [22] . Importantly, ADCC and neutralizing antibodies differ from each other in that ADCC antibody is directed against infected cells, rather than against cell-free virus, and cell death, rather than virus inhibition, is measured in ADCC assays. Indeed, some mAbs are discordant with respect to these two antibody functions [23] .
A number of early studies [24] [25] [26] [27] documented the presence of ADCC antibodies during HIV-1 infection. As expected, these antibodies have been largely directed against HIV Env, as there is a requirement for antigen expression on the surface of target cells [28, 29] . More recent studies indicate that Nef-specific ADCC antibodies arise during infection [30] . An assay that measures intracellular cytokines produced by NK cells in the presence of HIV antibody and exogenous antigen suggests that Vpu and Pol may also serve as a target for ADCC antibodies [31 ] ; this finding will need to be verified by documenting ADCC activity of anti-Vpu and anti-Pol antibodies using infected or transfected target cells.
A potential role for ADCC in modulating the course of HIV infection was first proposed on the basis of studies showing an inverse association between ADCC antibody levels and clinical stage of disease. The strongest evidence of a role for ADCC antibody in disease progression comes from a study by Baum et al. [20] of the Multicenter AIDS Cohort Study (MACS). In that study, rapid progressors had significantly lower ADCC antibody titers against CEM.NKR cells coated with gp120 than did nonrapid progressors at corresponding visits or nonprogressors at any visit. More recently, HIV-infected individuals with spontaneously undetectable viremia were shown to have higher ADCC antibody levels than viremic individuals, whereas neutralizing antibodies were either lower or similar, depending on the assay or virus strain used [18 ] . Direct evidence that ADCC antibodies might play a role in disease progression comes from a study of rhesus macaques with rapidly progressive disease [32] . The authors observed that passive infusion of simian immunodeficiency virus (SIV) IgG from SIVmac251-infected animals with a normal course of disease resulted in a transient decrease in viremia in the rapidly progressing animals; the kinetics of the antiviral effect suggested that ADCC activity of the infused antibody was killing virus-infected cells [32] .
In another study [33] using individuals from the MACS, those with the FcgRIIa RR genotype had a faster rate of progression to a CD4 þ cell count less than 200 cells/ml than did those with either the RH or HH genotypes; ADCC antibody activity was not measured. Interestingly, rituximab, whose antitumor activity is largely due to ADCC, may be less effective in treating lymphoma in patients with the lower affinity RR genotype [34] . Thus, the results of the MACS genotype study are consistent with a role for antibody-FcgR interactions in modulating the course of HIV infection. However, if the FcgRIIa polymorphism impacted progression of HIV infection because of its influence on ADCC, one might expect individuals with the RR genotype to have lower viral loads. In fact, there was no significant relationship between set point viral load and FcgRIIa genotype [33] . As anti-HIV ADCC antibody was not measured in the FcgR genotype study, it is possible that simultaneous consideration of ADCC antibody level and FcgR genotype might have predicted both viral load and disease progression.
The role of vaccine-induced ADCC antibody in preventing lentivirus infection has recently been evaluated. Using a replicating Ad5-SIV recombinant prime and gp120 boost that resulted in control of acute SIVmac251 viremia upon intrarectal challenge, the vaccine-induced ADCC antibody response (measured against target cells infected with a laboratory passaged SIV mac251 ) was associated with lower acute viremia [21] . In a study comparing oral/oral versus intranasal/oral priming with similar Ad5-SIV constructs followed, in both cases, by intramuscular gp120 boosting, the intranasal/oral regimen resulted in a small advantage in acute viremia control and in transiently higher ADCC antibody responses; differences between the two vaccine regimens were more apparent and sustained for ADCVI antibody responses [35] .
There has been no study correlating vaccine-induced ADCC responses with protection from HIV infection in humans. Of note, however, vaccination with recombinant gp120 (rgp120) results in ADCC antibody against gp120-coated target cells in most patients [36, 37] . On the contrary, DNA-or ALVAC-based HIV vaccines, without protein boosting, elicit little or no ADCC antibody [37, 38] .
Antibody-dependent cell-mediated virus inhibition
Similar to ADCC, ADCVI results from an interaction between a target cell, antibody, and an Fc receptorbearing effector cell. However, rather than being a measure of target cell death, as is the case with ADCC, ADCVI is a measure of the effect of antibody and effector cells on virus output from infected target cells [39, 40] . Thus, the readout in ADCVI assays is the percentage of virus inhibition due to a test antibody and effector cells relative to a negative control antibody and effector cells. This biologically relevant endpoint allows the use of any lentiviral strain capable of infecting the target cell. Much of the antiviral effect of ADCVI is due to target cell killing, and ADCVI and ADCC activities likely overlap considerably. However, noncytolytic mechanisms, such as FcgR-triggered production of b-chemokines, can also play a role in the virus inhibition measured in ADCVI assays [40] .
In a study [40] of individuals with acute HIV infection, we found that ADCVI antibodies developed as early as the first week after symptom onset or the first month after exposure. The ADCVI antibody response occurred with similar timing as the cytotoxic T-cell (CTL) response but much earlier than has been reported for the neutralizing antibody response [41, 42] . Furthermore, the ADCVI antibody response became more potent as viremia fell (in the absence of antiretroviral therapy), resulting in an inverse relationship between ADCVI antibody and plasma viremia [40] . ADCVI antibodies also appear to be more broadly reactive with different HIV strains than are antibodies measured in neutralizing assays [40] . Thus, it is possible that ADCVI contributes to the fall in viremia, in a manner similar to that proposed for CTLs. It should be noted, however, that in a separate study [41] we were unable to detect ADCVI antibodies in the first 40 days after exposure.
The role of ADCVI antibodies in preventing lentivirus infection has been studied in the SIV, simian/human immunodeficiency virus (SHIV), and HIV models. Passive infusion of SIV immune serum that prevented newborn macaques from an oral challenge with SIV mac251 was found to have no neutralizing activity against the challenge strain [43] . However, in an ADCVI assay, the infused serum had potent activity with a 50% inhibitory titer of 1 : 12 800 [23] . Moreover, the ADCVI activity resided in the IgG fraction, and the IgG fraction mediated antiviral activity when target cells and effector cells from the same animals were used [23] . In a direct evaluation of the role of Fc-FcgR interactions in preventing lentivirus infection, Hessell et al. [44] were able to protect eight of nine macaques from vaginal SHIV 163p3 challenge with native b12 infusion prior to challenge. Similarly, eight of nine macaques were protected by infusion of a b12 variant that was equivalent to native b12 with respect to FcgR binding and ADCVI and neutralizing activities but bound poorly to complement. However, using a second variant of b12 that bound poorly to both complement and to FcgR and did not mediate ADCVI -but retained neutralizing activity equivalent to native b12 -only five of eight animals were protected. Thus, maximum protection after passive antibody infusion requires ADCVI and/or other Fc-FcgR-mediated activity.
An evaluation of the ADCVI response in humans following rgp120 vaccination in the Vax004 trial revealed an inverse correlation between HIV infection rate and ADCVI antibody activity measured against a clinical R5 isolate of HIV-1 [45] . Thus, for every 10% increase in ADCVI activity, there was a 6.3% decrease in the hazard rate of infection (P ¼ 0.019). Moreover, the rate of infection was about two-fold less among individuals in the highest quartile of ADCVI antibody responses compared with those in the lowest quartile (hazard ratio ¼ 0.54, P ¼ 0.035). Thus, although, there was no overall efficacy in the Vax004 trial [46] , it is possible that individuals with the most potent vaccine-induced antibody responses had some degree of protection.
Conclusion
Antibody inhibitory activities related to Fc-FcgR interactions include blocking of virus infectivity via degradation of immune complexes in APCs, impairing virus replication by lysis of infected cells, and FcgR triggering of b-chemokine production. In addition to increasing the potency of the antiviral antibodies, Fc-FcgR interactions also increase their breadth [40] . Although this situation has not been studied systematically, it is possible that the increased potency and breadth is a consequence of the ability of Fc-FcgR interactions to occur when the Fab portion of antibody binds to any exposed Env component, even with relatively low affinity or avidity. This option is unlike the situation with classical neutralizing antibodies, which may need to bind with epitopes in such a way that there is interference with virus-receptor or virus-coreceptor interactions.
Fc-FcgR interactions play a critical role in the biological function of antibody and are likely to be instrumental in preventing or modulating lentiviral infection. Exploiting antibody responses that depend on Fc-FcgR interactions may help overcome some of the difficulties associated with vaccine development by widening the breadth and increasing the potency of the antibody response. Although the importance of generating optimal Fabantigen interactions cannot be overestimated, improving Fc-FcgR interactions through adjuvants, by directly altering the Fc segment of mAbs or by other strategies, provides another option for improving HIV vaccines and immunotherapies [47, 48, 49 ].
